The most interesting part of this decision by the Fed. Cir. (No. 24- 1061, Aug. 13, 2024) is that the court was faced with an argument by Sun that Allergan’s claims in U.S. Pat. No.11,311,516 et al. are invalid as failing to meet the WDR of § 112. Sun argued that the claims of certain of Allergan’s patent thicket were invalid because the specifications did not support a pharmaceutical composition containing the drug eluxadoline with a number of inert ingredients that did not include a “glidant.” In other words, Sun argued that there was no support for the absence of a glidant in any of the patent claims, a component Sun was apparently using in its compositions. Continue reading
Categories
Archives
Receive Email Updates
-
-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me
Warren D. Woessner Pages
Archives